Virios Therapeutics (Virios Therapeutics) Additional Paid-In Capital : $65.71 Mil(As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Virios Therapeutics Additional Paid-In Capital?

Virios Therapeutics's quarterly additional paid-in capital increased from Sep. 2023 ($65.43 Mil) to Dec. 2023 ($65.57 Mil) and increased from Dec. 2023 ($65.57 Mil) to Mar. 2024 ($65.71 Mil).

Virios Therapeutics's annual additional paid-in capital increased from Dec. 2021 ($58.43 Mil) to Dec. 2022 ($63.50 Mil) and increased from Dec. 2022 ($63.50 Mil) to Dec. 2023 ($65.57 Mil).

Virios Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Virios Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virios Therapeutics Additional Paid-In Capital Chart

Virios Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

57.91

58.43

63.50

65.57

Virios Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															63.66	64.11	65.43	65.57	65.71

Virios Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Virios Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Virios Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Virios Therapeutics (Virios Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virios Therapeutics Inc (NAS:VIRI) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

44 Milton Avenue, Alpharetta, GA, USA, 30009

Website

https://www.virios.com

Virios Therapeutics Inc is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia. The company is engaged in the development of its product, IMC-1, for people who are suffering from fibromyalgia.

Executives

William Pridgen	director	44 MILTON AVENUE, ALPHARETTA GA 30009
Gregory Scott Duncan	director, officer: Chief Executive Officer	44 MILTON AVENUE, ALPHARETTA GA 30009
Richard James Whitley	director	UAB, CHB 303, 1600 7TH AVENUE SOUTH, BIRMINGHAM AL 35233-1711
Angela Walsh	officer: VP of Finance	44 MILTON AVENUE, ALPHARETTA GA 30009
De La Rosa Abel	director	44 MILTON AVENUE, ALPHARETTA GA 30009
John C Thomas	director	8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
David R Keefer	director	44 MILTON AVENUE, ALPHARETTA GA 30009
Ralph Grosswald	officer: Vice President of Operations	44 MILTON AVENUE, ALPHARETTA GA 30009
Roger Michael Gendreau	officer: Chief Medical Officer	44 MILTON AVENUE, ALPHARETTA GA 30009
Richard Alan Burch	director	44 MILTON AVENUE, ALPHARETTA GA 30009